VESSL Therapeutics

Regenerative Medicine for Cardiovascular Diseases

Health Tech & Life Sciences
Non Active, Jun 2026 ceased to operate

Company Overview

Snapshot

Founded in October 2000 by Elad Tamir, Moshe Flugelman, and Basil Levis, VESSL Therapeutics operates with 1–10 employees. The company has raised a total of $30M across two funding rounds from seven investors. In April 2021, VESSL Therapeutics secured its most recent funding round.

Business overview

VESSL Therapeutics is a Health Tech & Life Sciences company focused on developing cell-based therapies for cardiovascular and other vascular-related conditions. Its core technology integrates cell types and genes to treat diseases such as peripheral artery disease, coronary artery disease, and renal disease requiring hemodialysis. The company's products, including MultiGeneAngio and MultiGeneGraft, are based on activating a patient's own cells with specific genes and reintroducing them, serving the healthcare market, particularly providers.

Strategic signal

In June 2026, VESSL Therapeutics ceased to operate. This indicates a significant and recent operational challenge, signaling to investors and innovation teams a complete halt in the company's development and commercialization efforts within the regenerative medicine space.

Company Intelligence Q&A

What is the current operational status of VESSL Therapeutics?
VESSL Therapeutics is currently non-active, having ceased operations in June 2026.
When was VESSL Therapeutics founded and by whom?
VESSL Therapeutics was founded in October 2000 by Elad Tamir, Moshe Flugelman, and Basil Levis.
What was the most recent funding event for VESSL Therapeutics?
In April 2021, VESSL Therapeutics secured a funding round with.
What are the primary products developed by VESSL Therapeutics?
VESSL Therapeutics develops MultiGeneAngio and MultiGeneGraft, which are cell-based therapies for cardiovascular and vascular-related conditions. MultiGeneAngio has completed two phase 1/2 clinical trials, and MultiGeneGraft has received an Investigational New Drug (IND) authorization from the FDA.
Which investors participated in the January 2009 funding round?
In January 2009, VESSL Therapeutics received funding from Eitan Wertheimer and Aviv Venture Capital.

External links